NEW DEVELOPMENTS TOWARD AN HIV VACCINE

As we have shared, our technology opens the way to address both sides of the HIV pandemic, namely (1) providing therapy for those who have the virus and (2) providing a vaccine that would prevent a person from ever becoming infected.

As to the second, within the last two weeks, we signed a Confidentiality Agreement with the world's largest producer of vaccines, a company that produces vaccines against 30 separate diseases and distributes them throughout the world. Under this Agreement, we have shared our confidential information about our technology and have received confirmation of this company’s interest in our technology and a desire to lead an effort to develop and test an anti-HIV vaccine using our technology. Additionally, this potential partner also has facilities and expertise relating to the first side of the equation. Specifically, it currently produces therapeutic antibodies against several diseases, although not against HIV. Thus, we are discussing a collaborative effort to complete the development and testing of our monoclonal antibody that is intended to provide a therapeutic cure for HIV.

All investments in our company support these types of collaborative efforts. Even without a partnership arrangement, we expect to complete successful animal trials with our monoclonal antibody within 24 months. Thus, we welcome all investments – each will play a significant role in moving us closer to an HIV therapy as well as an anti-HIV vaccine.